USFDA Cites Seven Observations at Cipla's Pithampur Manufacturing Plant

The U.S. Food and Drug Administration (USFDA) issued a seven-observation Form 483 to Cipla's Pithampur manufacturing facility following a follow-up inspection. This indicates potential deviations from good manufacturing practices, which could impact future regulatory actions or drug supply.